What Is Livagen?
Livagen is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Ala (KEDA), developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson family of tissue-specific peptides. It was originally isolated from bovine liver extracts and subsequently synthesized as a defined four-amino-acid compound targeting hepatic, lymphocyte, and gastrointestinal/immune cell populations. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Unlike classical receptor-ligand peptides, Livagen acts primarily at the chromatin and epigenetic level — interacting with DNA and histone architecture to de-condense heterochromatin in aged nuclei, restore gene expression profiles toward youthful patterns, and inhibit enzymes that degrade endogenous opioid peptides. It is often compared to Epitalon within the Khavinson peptide family, but is more focused on liver, GI, and immune systems rather than the pineal/circadian axis.
All published research comes from Russian bioregulator literature and preclinical models. There are no FDA-approved indications and no Western-style RCTs. All vendor-supplied Livagen is sold for research use only (RUO).
Mechanism of Action
Chromatin decondensation and gene activation: Livagen induces de-heterochromatinization in lymphocytes and hepatocytes — decondensing heterochromatin that has become pathologically compacted with age. It activates ribosomal genes and pericentromeric structural regions, and influences histone acetylation/methylation to restore transcriptional accessibility in aging liver and immune cells. The proposed outcome is restoration of youthful gene expression profiles in hepatic and lymphocyte populations; exact binding sites remain under investigation.
Hepatic regeneration and circadian biosynthesis: In aged rat hepatocyte cultures, nanomolar concentrations of Livagen significantly increased protein synthesis rates toward levels seen in young cells and repaired circadian biosynthesis rhythms disrupted by aging — effects not observed at supraphysiological concentrations, consistent with a regulatory rather than pharmacological mechanism.
Endogenous opioid system (EOS) support: Livagen inhibits enkephalin-degrading enzymes in human serum (IC₅₀ ≈ 20 µM) more efficiently than established peptidase inhibitors, raising endogenous enkephalin levels. This positions it alongside Epitalon within the Khavinson family's proposed pain, mood, and immune-modulation framework. Antioxidant and anti-inflammatory effects have been hypothesized but are not yet characterized at a mechanistic level.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols (Educational Only)
This member section describes parameters reported in the research literature.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Reported Research Time Points
This member section summarizes reported research time points.
Research Citations
- Effect of the peptide Livagen on chromatin activation in lymphocytes of old and young people
Khavinson VKh et al., 2002, Bull Exp Biol Med - Peptide Livagen activates ribosomal genes in human lymphocytes
Khavinson VKh, Malinin VV, 2001, Bull Exp Biol Med - Comparison of effects of Epithalon and Livagen on endogenous opioid system in humans
Khavinson VKh et al., 2004, Bull Exp Biol Med - Effects of peptide bioregulators on liver protein biosynthesis in old rats
Khavinson VKh, Tarnovskaya SI et al., 2005, Bull Exp Biol Med - Khavinson development attribution. Existing stored entry reference; Existing stored entry reference
Livagen is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Ala (KEDA) , developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson family of tissue-specific peptides. It was originally isolated from bovine liver extracts and subsequently synthesized as a defined four-amino-acid compound targeting hepatic, lymphocyte, and gastrointestinal/immune cell populations.